Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Sling Therapeutics just secured $123 million to push its experimental oral drug, linsitinib, into a late-stage trial for thyroid eye disease. If approved, it would be the first-ever oral treatment for the condition — a potential game-changer over current IV options like Tepezza and Lumvoa. The trial will enroll ~130 adults with moderate-to-severe active disease.
Sling Therapeutics has raised $123 million in a Series C funding round to fund a late-stage clinical trial of linsitinib, its experimental oral treatment for thyroid eye disease — a condition that causes painful inflammation, eye bulging, and potential vision loss. The round was led by Forbion, with participation from TPG Life Sciences Innovations and Sectoral Asset Management.
The pivotal trial will enroll approximately 130 adults with moderate-to-severe active thyroid eye disease, who will receive either 150 mg of linsitinib or a placebo twice daily for 24 weeks. An earlier trial showed linsitinib successfully reduced eye bulging and demonstrated a cleaner safety profile compared to existing treatments, which have been linked to hearing loss and changes in blood sugar and menstrual cycles.
By the Numbers:
Why it matters: If approved, linsitinib would be the first oral drug for thyroid eye disease, offering a more convenient and potentially safer alternative to existing intravenous biologics — particularly for patients concerned about hearing loss or for whom IV therapy isn't practical.
